A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines

Paola Russo, Antonio D Ligsay, Remigio Olveda, Seuk Keun Choi, Deok Ryun Kim, Ju Yeon Park, Ju Yeong Park, Khalid Ali Syed, Ayan Dey, Yang Hee Kim, Sung Hee Lee, Jayoung Kim, Yun Chon, Laura Digilio, Chan Wha Kim, Jean-Louis Excler, Paola Russo, Antonio D Ligsay, Remigio Olveda, Seuk Keun Choi, Deok Ryun Kim, Ju Yeon Park, Ju Yeong Park, Khalid Ali Syed, Ayan Dey, Yang Hee Kim, Sung Hee Lee, Jayoung Kim, Yun Chon, Laura Digilio, Chan Wha Kim, Jean-Louis Excler

Abstract

Background: To contribute to the global demand for oral cholera vaccine (OCV), the production of Euvichol® was scaled up with elimination of thimerosal. To demonstrate the equivalence of the variations, a study was carried out in the Philippines.

Methods: Healthy male and female adults and children in Manila were randomized to receive two doses of Euvichol® two weeks apart from either the 100L (Comparator) or the 600L (Test) variation. Primary and secondary immunogenicity endpoints were respectively geometric mean titer (GMT) of vibriocidal antibodies (two weeks post second dose) and seroconversion rate (two weeks after each dose) against O1 Inaba, Ogawa, and O139 serogroups. The GMT of vibriocidal antibodies against O1 Inaba, Ogawa, and O139 two weeks post first dose was also measured. To show the equivalence of two variations of Euvichol®, the ratio of GMT and the difference of seroconversion rate between Test and Comparator vaccines were tested with equivalence margin of [0.5, 2.0] for GMT ratio and of 15% for seroconversion rate, respectively. Safety assessment included solicited reactogenicity within 6 days after each dose and unsolicited and serious adverse events.

Results: A total of 442 participants were enrolled. For the overall population, equivalence between Test and Comparator was demonstrated for vibriocidal antibody response against O1 Inaba and Ogawa serotypes and O139 serogroup in both modified intention-to-treat (mITT) and per protocol analysis, since the 95% confidence intervals (CI) of GMT to any serotypes were within the lower and upper boundary [0.5, 2.0]. Seroconversion rates after two doses also showed equivalence for O1 Inaba, Ogawa, and O139. The vaccine was safe and well tolerated, similarly between the two groups.

Conclusion: The study results support the equivalence of the 600L Euvichol® to the 100L formulation in healthy children and adults. The 600L Euvichol® is safe and immunogenic in adults and children. ClinicalTrials.gov registration number: NCT02502331.

Keywords: Cholera; Equivalence; Euvichol; Oral cholera vaccine; The Philippines.

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Flow Diagram of Participants Disposition (CONSORT flow diagram). Note: d: mITT analysis set [excluded: 3 adults (2 withdrawn by participants’ own will and 1 lost follow-up) and 2 children (withdrawn by participants’ own will) in Test vaccine group, and 1 child (withdrawn by participants’ own will) in Comparator vaccine group], e: PP analysis set [excluded: 5 adults (1 withdrawn by own will, 1 outside visit window, and 3 recruited out of study area) and 8 children (1 withdrawn due to lost to follow-up, 1 missed vaccination due to safety issue, 4 spat out the vaccine, 1 was administered wrong IP, and 1 due to outside visit window) in Test vaccine group; 2 adults (1 missed vaccination due to pregnancy and 1 was recruited out of study area) and 3 children (1 missed vaccination due to SAE and 2 spat out) in Comparator vaccine group].
Fig. 2
Fig. 2
Plot of geometric mean ratio (GMR) of titers two weeks post second dose (mITT and PP analysis sets).

References

    1. Ali M., Nelson A.R., Lopez A.L., Sack D.A. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9:e0003832.
    1. Weekly epidemiological record Cholera vaccines: WHO position paper, 26 MARCH 2010, 85th YEAR, 85e ANNÉE No. 13, 2010;85:117–12.
    1. Weekly epidemiological record. Cholera vaccines: WHO position paper – August 2017, 92th YEAR - No 34, 2017;92:477–500.
    1. World Health Assembly. Resolution 64.18. Cholera: mechanism for control and prevention. Sixty-fourth World Health Assembly, 17 March 2011. Geneva, Switzerland: World Health Organization, 2011.
    1. World Health Organization. WHO technical working group on the creation of an oral cholera vaccine stockpile: meeting report. Geneva SWDPS, 2012.
    1. Desai S.N., Pezzoli L., Martin S., Costa A., Rodriguez C., Legros D. A second affordable oral cholera vaccine: implications for the global vaccine stockpile. Lancet Glob Health. 2016;4:e223–e224.
    1. Qadri F., Wierzba T.F., Ali M., Chowdhury F., Khan A.I., Saha A. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med. 2016;374:1723–1732.
    1. Baik Y.O., Choi S.K., Kim J.W., Yang J.S., Kim I.Y., Kim C.W. Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea. J Korean Med Sci. 2014;29:494–501.
    1. Baik Y.O., Choi S.K., Olveda R.M., Espos R.A., Ligsay A.D., Montellano M.B. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine. 2015;33:6360–6365.
    1. International Coordinating Group oral cholera vaccine. Annual meeting report. 11-12 June 2015 – Geneva.
    1. Kupferschmidt K. Cholera vaccine faces major test in Yemen. Science. 2017;356:1316–1317.
    1. Guidelines on regulatory expectations related to the elimination, reduction or replacement of thiomersal in vaccines. WHO Technical Report Series (TRS) 926 Annex 4. 2004.
    1. Julious S.A. Tutorial in Biostatistics: Sample sizes for clinical trials with Normal data. Stat Med. 2004;23:1921–1986.
    1. Yang J.S., Choi S., Kim D.D., Kang S.S., Yun C.H., Lee K. A duplex vibriocidal assay to simultaneously measure bactericidal antibody titers against Vibrio cholerae O1 Inaba and Ogawa serotypes. J Microbiol Method. 2009;79:289–294.
    1. Yang J.S., Kim H.J., Yun C.H., Kang S.S., Im J., Kim H.S. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses. J Microbiol Methods. 2007;71:141–146.
    1. United States Food and Drug Administration. BIOEQUIVALENCE GUIDANCE. Docket No. 94D-0401
    1. WHO Expert Committee on Biological Standardization. TRS 999; 2015.
    1. Martin Bland J., Altman Douglas G. Statistics notes: Transformations, means, and confidence intervals. BMJ. 1996;312:1079.
    1. Matias W.R., Falkard B., Charles R.C., Mayo-Smith L.M., Teng J.E., Xu P. Antibody secreting cell responses following vaccination with bivalent oral cholera vaccine among haitian adults. PLoS Negl Trop Di. 2016;10:e0004753.
    1. Saha A., Chowdhury M.I., Khanam F., Bhuiyan M.S., Chowdhury F., Khan A.I. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine. 2011;29:8285–8292.
    1. Introduction to Drug Utilization Research; WHO International Working Group for Drug Statistics Methodology. Printed in Oslo N; 2003.
    1. Capeding M.R.Z., Gonzales M., Dhingra M.S., D'Cor N.A., Midde V.J., Patnaik B.N. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines. Hum Vaccin Immunother. 2017;13:2232–2239.
    1. Qadri F., Svennerholm A.M., Shamsuzzaman S., Bhuiyan T.R., Harris J.B., Ghosh A.N. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh. Infect Immun. 2005;73:6577–6583.
    1. Losonsky G.A., Lim Y., Motamedi P., Comstock L.E., Johnson J.A., Morris J.G., Jr Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin Diagn Lab Immunol. 1997;4:264–269.
    1. Qadri F., Mohi G., Hossain J., Azim T., Khan A.M., Salam M.A. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol. 1995;2:685–688.
    1. [accessed on 02.23.18].

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner